BridgeBio Pharma, Inc. (NASDAQ:BBIO) CEO Sells $2,517,750.00 in Stock

BridgeBio Pharma, Inc. (NASDAQ:BBIO) CEO Neil Kumar sold 75,000 shares of BridgeBio Pharma stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $33.57, for a total transaction of $2,517,750.00. Following the sale, the chief executive officer now directly owns 5,023,447 shares of the company’s stock, valued at $168,637,115.79. This trade represents a 1.47 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Neil Kumar also recently made the following trade(s):

• On Wednesday, February 19th, Neil Kumar sold 31,543 shares of BridgeBio Pharma stock. The shares were sold at an average price of $36.14, for a total transaction of $1,139,964.02.
• On Tuesday, January 28th, Neil Kumar sold 326,932 shares of BridgeBio Pharma stock. The shares were sold at an average price of $36.29, for a total transaction of $11,864,362.28.

BridgeBio Pharma Price Performance

BridgeBio Pharma stock opened at $34.90 on Friday. The firm has a market cap of $6.64 billion, a price-to-earnings ratio of -12.25 and a beta of 1.07. BridgeBio Pharma, Inc. has a fifty-two week low of $21.62 and a fifty-two week high of $39.47. The firm has a fifty day moving average price of $32.68 and a two-hundred day moving average price of $28.29.

BridgeBio Pharma (NASDAQ:BBIO) last released its earnings results on Thursday, February 20th. The company reported ($1.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.09) by ($0.22). The business had revenue of $5.88 million for the quarter, compared to analysts’ expectations of $4.04 million. As a group, sell-side analysts expect that BridgeBio Pharma, Inc. will post -3.67 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Creative Planning bought a new position in shares of BridgeBio Pharma during the 3rd quarter worth about $772,000. Allspring Global Investments Holdings LLC increased its holdings in shares of BridgeBio Pharma by 17.7% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 5,322 shares of the company’s stock worth $135,000 after purchasing an additional 801 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of BridgeBio Pharma by 21.7% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,801 shares of the company’s stock worth $170,000 after purchasing an additional 1,214 shares during the period. China Universal Asset Management Co. Ltd. increased its holdings in shares of BridgeBio Pharma by 64.5% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 36,165 shares of the company’s stock worth $921,000 after purchasing an additional 14,181 shares during the period. Finally, Emerald Mutual Fund Advisers Trust increased its holdings in shares of BridgeBio Pharma by 50.8% during the 3rd quarter. Emerald Mutual Fund Advisers Trust now owns 751,355 shares of the company’s stock worth $19,129,000 after purchasing an additional 253,101 shares during the period. Institutional investors and hedge funds own 99.85% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on BBIO. HC Wainwright reissued a “buy” rating and set a $49.00 target price on shares of BridgeBio Pharma in a research note on Thursday, February 13th. Scotiabank lifted their target price on shares of BridgeBio Pharma from $49.00 to $52.00 and gave the company a “sector outperform” rating in a research note on Friday, February 21st. Evercore ISI lifted their target price on shares of BridgeBio Pharma from $45.00 to $50.00 and gave the company an “outperform” rating in a research note on Monday, December 23rd. Citigroup lifted their price objective on shares of BridgeBio Pharma from $45.00 to $49.00 and gave the company a “buy” rating in a research note on Friday, February 21st. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $95.00 price objective on shares of BridgeBio Pharma in a research note on Friday, February 21st. One research analyst has rated the stock with a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat, BridgeBio Pharma presently has a consensus rating of “Moderate Buy” and a consensus price target of $51.67.

About BridgeBio Pharma

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.